SG11201702110RA - Methods and compositions for inducing protective immunity against human immunodeficiency virus infection - Google Patents

Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Info

Publication number: SG11201702110RA
Authority: SG; Singapore
Prior art keywords: compositions; methods; immunodeficiency virus; virus infection; human immunodeficiency
Prior art date: 2014-09-26

Application number

SG11201702110RA

Inventor

Dan Barouch

Johanna Schuitemaker

Maria Grazia Pau

Manen Danielle Van

Frank Tomaka

Jennifer Anne Hendriks

Original Assignee

Beth Israel Deaconess Medical Ct Inc

Janssen Vaccines & Prevention Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-26

Filing date

2015-09-24

Publication date

2017-04-27

2015-09-24 Application filed by Beth Israel Deaconess Medical Ct Inc, Janssen Vaccines & Prevention Bv filed Critical Beth Israel Deaconess Medical Ct Inc

2017-04-27 Publication of SG11201702110RA publication Critical patent/SG11201702110RA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SG11201702110RA 2014-09-26 2015-09-24 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection SG11201702110RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462056059P	2014-09-26	2014-09-26
PCT/US2015/051891 WO2016049287A1 (en)	2014-09-26	2015-09-24	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Publications (1)

Publication Number	Publication Date
SG11201702110RA true SG11201702110RA (en)	2017-04-27

Family

ID=55581992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201702110RA SG11201702110RA (en)	2014-09-26	2015-09-24	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Country Status (28)

Country	Link
US (4)	US10137191B2 (en)
EP (2)	EP3197489B1 (en)
JP (2)	JP6438575B2 (en)
KR (2)	KR102159626B1 (en)
CN (2)	CN106999571B (en)
AP (1)	AP2017009846A0 (en)
AU (2)	AU2015320574B2 (en)
BR (1)	BR112017005917A2 (en)
CA (1)	CA2961024A1 (en)
CY (1)	CY1124254T1 (en)
DK (1)	DK3197489T3 (en)
EA (2)	EA202092521A1 (en)
ES (1)	ES2865150T3 (en)
HR (1)	HRP20210608T1 (en)
HU (1)	HUE053585T2 (en)
IL (2)	IL251114B (en)
LT (1)	LT3197489T (en)
MA (1)	MA40765B1 (en)
MX (2)	MX2017003946A (en)
MY (1)	MY175620A (en)
PH (1)	PH12017500449A1 (en)
PL (1)	PL3197489T3 (en)
PT (1)	PT3197489T (en)
RS (1)	RS61902B1 (en)
SG (1)	SG11201702110RA (en)
SI (1)	SI3197489T1 (en)
WO (1)	WO2016049287A1 (en)
ZA (1)	ZA201702053B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201702110RA (en)	2014-09-26	2017-04-27	Beth Israel Deaconess Medical Ct Inc	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MA40783A (en)	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS
TWI707039B (en)	2015-12-15	2020-10-11	荷蘭商傑森疫苗防護公司	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
WO2017143016A1 (en)	2016-02-16	2017-08-24	Geovax Inc.	Multivalent hiv vaccine boost compositions and methods of use
KR102389489B1 (en)	2016-06-16	2022-04-22	얀센 백신스 앤드 프리벤션 비.브이.	HIV Vaccine Formulations
CA3035759A1 (en) *	2016-09-02	2018-03-08	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2018050747A1 (en)	2016-09-15	2018-03-22	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutations
WO2018229711A1 (en)	2017-06-15	2018-12-20	Janssen Vaccines & Prevention B.V.	Poxvirus vectors encoding hiv antigens, and methods of use thereof
CN110891601A (en)	2017-07-19	2020-03-17	扬森疫苗与预防公司	Trimer-stable HIV envelope protein mutations
US20190022212A1 (en)	2017-07-21	2019-01-24	Beth Israel Deaconess Medical Center, Inc.	Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) *	2017-09-18	2019-03-21	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2020064621A1 (en)	2018-09-25	2020-04-02	Janssen Vaccines & Prevention B.V.	Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
US20220211835A1 (en) *	2019-04-17	2022-07-07	The Wistar Institute	Replication Deficient Adenoviral Vectors for HIV Vaccine Applications
WO2020237052A1 (en) *	2019-05-22	2020-11-26	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
AU2020279988A1 (en) *	2019-05-22	2021-12-23	Aelix Therapeutics, S.L.	Dosage regimens for vaccines
AU2020315598A1 (en)	2019-07-16	2022-03-03	Gilead Sciences, Inc.	HIV vaccines and methods of making and using
US11857619B2 (en) *	2019-11-07	2024-01-02	Janssen Vaccines & Prevention B.V.	Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein
AU2022207422A1 (en)	2021-01-14	2023-07-27	Gilead Sciences, Inc.	Hiv vaccines and methods of using
WO2023198815A1 (en)	2022-04-14	2023-10-19	Janssen Vaccines & Prevention B.V.	Sequential administration of adenoviruses

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
CA1341245C (en)	1988-01-12	2001-06-05	F. Hoffmann-La Roche Ag	Recombinant vaccinia virus mva
US5298416A (en)	1989-01-18	1994-03-29	British Technology Group Ltd.	Attenuated polioviruses
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en)	1995-12-07	2002-11-12	Diversa Corporation	Non-stochastic generation of genetic vaccines
AU4255397A (en)	1996-09-06	1998-03-26	Trustees Of The University Of Pennsylvania, The	Chimpanzee adenovirus vectors
GB0023203D0 (en)	2000-09-21	2000-11-01	Isis Innovation	Vaccination method
DE60045138D1 (en)	1999-05-17	2010-12-02	Crucell Holland Bv	Recombinant adenovirus of the Ad26 serotype
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
US6710173B1 (en)	1999-06-25	2004-03-23	Progenics Pharmaceuticals, Inc.	Stabilized viral envelope proteins and uses thereof
EP1214333A4 (en)	1999-09-17	2005-01-19	Dana Farber Cancer Inst Inc	Stabilized soluble glycoprotein trimers
EP1598425A1 (en)	2000-11-23	2005-11-23	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant
WO2003004657A1 (en)	2001-07-05	2003-01-16	Chiron Corporation	Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CN102409063A (en)	2001-12-04	2012-04-11	巴法里安诺迪克有限公司	Flavivirus ns1 subunit vaccine
EA010828B1 (en)	2002-04-25	2008-12-30	Круселл Холланд Б.В.	Recombinant adenovirus vectors and methods for the production thereof and use
DK1497440T3 (en)	2002-04-25	2008-12-01	Crucell Holland Bv	Stable adenoviral vectors and methods of propagation thereof
AU2003291402A1 (en)	2002-11-07	2004-06-03	Beth Israel Deaconess Medical Center	MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
JP2006509039A (en)	2002-12-03	2006-03-16	ユニバーシティオブマサチューセッツ	Multivalent primary HIV-1 glycoprotein DNA vaccine and vaccination method
EP2371380A1 (en)	2003-03-28	2011-10-05	The Government of the United States of America, represented by The Secretary, Department of Health and Human Services	MVA expressing modified hiv envelope, gag, and pol genes
EP1667631A4 (en) *	2003-09-15	2010-04-14	Novartis Vaccines & Diagnostic	Combination approaches for generating immune responses
WO2005052119A2 (en)	2003-11-19	2005-06-09	Beth Israel Deaconess Medical Center	Adjuvants of immune response
EP2163260B1 (en)	2004-01-23	2017-03-15	MSD Italia S.r.l.	Chimpanzee adenovirus vaccine carriers
EP1766097A4 (en)	2004-06-15	2008-03-19	Progenics Pharm Inc	Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
EP2397490B1 (en)	2004-07-16	2013-09-04	THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
AU2005279799A1 (en)	2004-08-27	2006-03-09	Emory University	Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes
EP1799836B1 (en)	2004-10-13	2010-12-22	Crucell Holland B.V.	Improved adenoviral vectors and uses thereof
EP1814583A2 (en) *	2004-11-01	2007-08-08	Novartis Vaccines and Diagnostics, Inc.	Combination approaches for generating immune responses
WO2007005934A2 (en)	2005-07-06	2007-01-11	University Of Maryland Biotechnology Institute	Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CA2620874A1 (en)	2005-08-23	2007-03-01	The Regents Of The University Of California	Polyvalent vaccine
US20100143302A1 (en)	2006-03-16	2010-06-10	Crucell Holland B.V.	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20110076298A1 (en)	2006-06-19	2011-03-31	Olson William C	Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en)	2006-10-23	2008-05-29	Progenics Pharmaceuticals, Inc.	Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2008140579A2 (en)	2006-11-17	2008-11-20	New York University	Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
AU2008223951B2 (en)	2007-03-02	2014-03-27	Glaxosmithkline Biologicals S.A.	Novel method and compositions
DK2340038T3 (en)	2008-10-10	2018-02-26	Childrens Medical Ct Corp	BIOCHEMICALLY STABILIZED HIV-1-ENV TRIMER VACCINE
US9017691B2 (en)	2008-11-18	2015-04-28	Beth Israel Deaconess Medical Center	Antiviral vaccines with improved cellular immunogenicity
WO2010085984A1 (en)	2009-02-02	2010-08-05	Okairos Ag	Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
NZ594355A (en)	2009-02-02	2012-11-30	Okairos Ag	Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en)	2009-02-18	2010-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic hiv/siv gag proteins and uses thereof
US9241986B2 (en)	2010-01-04	2016-01-26	Kj Biosciences Llc	DPS fusion proteins for use in vaccines and diagnostics
EP2529010B1 (en)	2010-01-28	2017-04-19	Bavarian Nordic A/S	Vaccinia virus mutants containing the major genomic deletions of mva
EP2536829B1 (en) *	2010-02-15	2016-04-06	Crucell Holland B.V.	Method for the production of Ad26 adenoviral vectors
CA3201524A1 (en)	2010-08-31	2012-03-08	Theraclone Sciences, Inc.	Human immunodeficiency virus (hiv)-neutralizing antibodies
AU2011316164B2 (en)	2010-10-15	2016-01-14	Bavarian Nordic A/S	Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
DK2655604T3 (en)	2010-12-14	2018-08-06	Us Gov Health & Human Services	ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
WO2013036791A2 (en)	2011-09-09	2013-03-14	Beth Israel Deaconess Medical Center, Inc.	Modified adenoviral vectors and methods of treatment using same
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013055908A1 (en)	2011-10-12	2013-04-18	The Scripps Research Institute	An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en)	2012-09-19	2014-03-27	Beth Israel Deaconess Medical Center, Inc.	Viruses associated with immunodeficiency and enteropathy and methods using same
NZ708144A (en)	2012-11-16	2020-03-27	Beth Israel Deaconess Medical Ct Inc	Recombinant adenoviruses and use thereof
MY187152A (en) *	2013-01-07	2021-09-06	Beth Israel Deaconess Medical Ct Inc	Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
US10248758B2 (en)	2013-02-07	2019-04-02	University Of Washington Through Its Center For Commercialization	Self-assembling protein nanostructures
US10376583B2 (en)	2013-09-30	2019-08-13	Beth Israel Deaconess Medical Center, Inc.	Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
CN103992396B (en) *	2014-04-17	2017-03-29	南开大学	A kind of potential efficiently immunogenic preparation methods of 1 CRF07 BC gp140 of Recombinant HIV
EP3189067B1 (en)	2014-09-04	2021-05-19	The United States of America, as represented by The Secretary, Department of Health and Human Services	Recombinant hiv-1 envelope proteins and their use
SG11201702110RA (en)	2014-09-26	2017-04-27	Beth Israel Deaconess Medical Ct Inc	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
US9630994B2 (en)	2014-11-03	2017-04-25	University Of Washington	Polypeptides for use in self-assembling protein nanostructures
TWI707039B (en)	2015-12-15	2020-10-11	荷蘭商傑森疫苗防護公司	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CA3035759A1 (en) *	2016-09-02	2018-03-08	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

2015
- 2015-09-24 SG SG11201702110RA patent/SG11201702110RA/en unknown
- 2015-09-24 EA EA202092521A patent/EA202092521A1/en unknown
- 2015-09-24 AP AP2017009846A patent/AP2017009846A0/en unknown
- 2015-09-24 US US14/863,808 patent/US10137191B2/en active Active
- 2015-09-24 EP EP15845233.4A patent/EP3197489B1/en active Active
- 2015-09-24 HU HUE15845233A patent/HUE053585T2/en unknown
- 2015-09-24 CA CA2961024A patent/CA2961024A1/en active Pending
- 2015-09-24 PL PL15845233T patent/PL3197489T3/en unknown
- 2015-09-24 WO PCT/US2015/051891 patent/WO2016049287A1/en active Application Filing
- 2015-09-24 SI SI201531597T patent/SI3197489T1/en unknown
- 2015-09-24 EP EP21157436.3A patent/EP3868398A1/en not_active Withdrawn
- 2015-09-24 CN CN201580063229.2A patent/CN106999571B/en not_active Expired - Fee Related
- 2015-09-24 KR KR1020197010330A patent/KR102159626B1/en active IP Right Grant
- 2015-09-24 MA MA40765A patent/MA40765B1/en unknown
- 2015-09-24 JP JP2017516371A patent/JP6438575B2/en not_active Expired - Fee Related
- 2015-09-24 MY MYPI2017700998A patent/MY175620A/en unknown
- 2015-09-24 KR KR1020177011034A patent/KR101971808B1/en active IP Right Grant
- 2015-09-24 ES ES15845233T patent/ES2865150T3/en active Active
- 2015-09-24 BR BR112017005917A patent/BR112017005917A2/en not_active Application Discontinuation
- 2015-09-24 AU AU2015320574A patent/AU2015320574B2/en not_active Ceased
- 2015-09-24 DK DK15845233.4T patent/DK3197489T3/en active
- 2015-09-24 LT LTEP15845233.4T patent/LT3197489T/en unknown
- 2015-09-24 RS RS20210546A patent/RS61902B1/en unknown
- 2015-09-24 CN CN202011101485.5A patent/CN112121160A/en active Pending
- 2015-09-24 EA EA201790717A patent/EA037583B1/en unknown
- 2015-09-24 PT PT158452334T patent/PT3197489T/en unknown
- 2015-09-24 MX MX2017003946A patent/MX2017003946A/en unknown
2017
- 2017-03-09 PH PH12017500449A patent/PH12017500449A1/en unknown
- 2017-03-13 IL IL251114A patent/IL251114B/en active IP Right Grant
- 2017-03-23 ZA ZA2017/02053A patent/ZA201702053B/en unknown
- 2017-03-24 MX MX2020013153A patent/MX2020013153A/en unknown
2018
- 2018-05-02 US US15/968,834 patent/US10471137B2/en active Active
- 2018-11-15 JP JP2018214706A patent/JP6625716B2/en not_active Expired - Fee Related
- 2018-11-23 AU AU2018267669A patent/AU2018267669B2/en not_active Ceased
2019
- 2019-03-31 IL IL265733A patent/IL265733B/en active IP Right Grant
- 2019-10-04 US US16/593,658 patent/US11207400B2/en active Active
2021
- 2021-04-16 HR HRP20210608TT patent/HRP20210608T1/en unknown
- 2021-05-07 CY CY20211100391T patent/CY1124254T1/en unknown
- 2021-12-06 US US17/457,705 patent/US20220096622A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3197489A1 (en)	2017-08-02
JP2019038849A (en)	2019-03-14
WO2016049287A1 (en)	2016-03-31
EA202092521A1 (en)	2021-05-31
JP6625716B2 (en)	2019-12-25
JP6438575B2 (en)	2018-12-12
KR102159626B1 (en)	2020-09-25
CN106999571A (en)	2017-08-01
IL251114B (en)	2019-05-30
AP2017009846A0 (en)	2017-03-31
AU2015320574A1 (en)	2017-04-06
EP3197489B1 (en)	2021-02-17
US20180250385A1 (en)	2018-09-06
JP2017531627A (en)	2017-10-26
MA40765A (en)	2017-08-02
HRP20210608T1 (en)	2021-06-11
EA037583B1 (en)	2021-04-16
PL3197489T3 (en)	2021-11-08
CN106999571B (en)	2020-10-02
PH12017500449A1 (en)	2017-07-31
AU2018267669B2 (en)	2020-03-05
IL265733B (en)	2021-05-31
US11207400B2 (en)	2021-12-28
ZA201702053B (en)	2021-09-29
KR101971808B1 (en)	2019-04-23
CY1124254T1 (en)	2022-07-22
IL251114A0 (en)	2017-04-30
MX2020013153A (en)	2021-02-18
EP3868398A1 (en)	2021-08-25
AU2018267669A1 (en)	2018-12-13
AU2015320574B2 (en)	2018-12-06
SI3197489T1 (en)	2021-08-31
NZ730841A (en)	2021-08-27
CN112121160A (en)	2020-12-25
US20220096622A1 (en)	2022-03-31
RS61902B1 (en)	2021-06-30
MX2017003946A (en)	2017-12-20
EA201790717A1 (en)	2018-02-28
LT3197489T (en)	2021-07-26
IL265733A (en)	2019-05-30
KR20170066454A (en)	2017-06-14
MY175620A (en)	2020-07-02
HUE053585T2 (en)	2021-07-28
DK3197489T3 (en)	2021-04-19
MA40765B1 (en)	2021-04-30
US10137191B2 (en)	2018-11-27
KR20190042736A (en)	2019-04-24
US10471137B2 (en)	2019-11-12
CA2961024A1 (en)	2016-03-31
ES2865150T3 (en)	2021-10-15
US20160089432A1 (en)	2016-03-31
BR112017005917A2 (en)	2017-12-12
US20200030437A1 (en)	2020-01-30
EP3197489A4 (en)	2018-03-14
PT3197489T (en)	2021-04-30

Publication	Publication Date	Title
IL265733B (en)	2021-05-31	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
ZA201700165B (en)	2019-06-26	Influenza virus vaccines and uses thereof
ZA201700952B (en)	2018-12-19	Indoles for use in influenza virus infection
PL3262037T3 (en)	2020-10-19	A new quinoline derivative for use in the treatment and prevention of viral infections
ZA201701815B (en)	2021-01-27	Methods and compositions for inducing protective immunity against filovirus infection
SG11201610443WA (en)	2017-01-27	Influenza virus vaccines and uses thereof
EP3139921A4 (en)	2018-02-14	Benzomorphan analogs and use thereof
SG11201702116VA (en)	2017-04-27	Viral rna segments as immunomodulatory agents and vaccine components
SG11201701256RA (en)	2017-03-30	Vaccine compositions against dengue virus diseases
HK1252343A1 (en)	2019-05-24	Compositions and methods for the treatment of viral infection
IL246643B (en)	2020-02-27	Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
IL249705B (en)	2021-03-25	Influenza virus vaccines and uses thereof
IL249704A0 (en)	2017-02-28	Influenza virus vaccines and uses thereof
AU2014900488A0 (en)	2014-02-27	Agents and methods for inhibiting virus infection